3β-HSD5 Inhibitors

Chemical inhibitors of 3β-HSD5 play a crucial role in modulating the steroidogenesis pathway by directly or indirectly impacting the enzyme's function. Trilostane stands out by competitively binding to the active site of 3β-HSD5, which prevents the enzyme from converting pregnenolone into progesterone, effectively inhibiting the steroidogenic process. Similarly, Epostane exerts its inhibitory effect by covalently binding to 3β-HSD5, making it unable to catalyze the synthesis of downstream steroid hormones. Cyanoketone takes a different approach by irreversibly inhibiting 3β-HSD5, targeting the NAD+ binding site and leading to a permanent loss of enzymatic activity. Metyrapone, although traditionally known for inhibiting 11-beta-hydroxylation, indirectly reduces 3β-HSD5 activity by disrupting feedback mechanisms crucial for the enzyme's regulation.

Ketoconazole and Abiraterone target cytochrome P450 enzymes, which are essential for the enzymatic transformations carried out by 3β-HSD5. Ketoconazole does this non-selectively, while Abiraterone specifically inhibits the cytochrome P450 17A1 enzyme, a component vital for androgen synthesis by 3β-HSD5. Aminoglutethimide reduces the availability of steroid precursors, thereby lowering the substrate levels necessary for 3β-HSD5 activity. Telapristone inhibits 3β-HSD5 indirectly by antagonizing progesterone receptors, which are part of the feedback mechanism regulating the enzyme's expression and activity. Selegiline, through its metabolite desmethylselegiline, disrupts neurosteroid synthesis, a process that depends on the proper functioning of 3β-HSD5. Lastly, Letrozole, Exemestane, and Anastrozole are aromatase inhibitors that decrease estrogen synthesis, resulting in a hormonal imbalance that influences the regulatory mechanisms controlling 3β-HSD5. By lowering estrogen levels, these inhibitors create a biochemical environment that is less conducive to the optimal activity of 3β-HSD5, thus leading to a functional inhibition of this pivotal enzyme in the steroidogenic pathway.